3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Lenalidomide
2
Cyclophosphamide
2
ibrutinib
1
fludarabine
1
Vincristine
1
Ropivacaine
1
Rituximab
1
R-CHOP protocol
1
Prednisone
1
Nivolumab
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Maintenance
1
Magnetic Resonance Spectroscopy
1
Leukapheresis
1
JNJ-64619178
1
JNJ-64264681
1
Inosine Monophosphate
1
Etoposide
1
Educational Status
1
Doxorubicin
1
Decitabine
1
Brentuximab Vedotin
1
Blood Specimen Collection
1
Biopsy, Fine-Needle
1
Bendamustine Hydrochloride
1
Angptl4 protein, mouse
1
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
Inosine Monophosphate
×
Lymphoid
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled